TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Synergistic Effect of Dexmedetomidine on Propofol for Sedation for Pediatric Endoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 7-18 years who are scheduled for upper or lower endoscopic procedures at Boston Children's Hospital and meets criteria to receive dexmedetomidine or propofol sedation for upper and lower endoscopic procedures~* Provides written consent to participate in the research study~* For females of childbearing age, pregnancy test is negative~Exclusion Criteria:~* Do not meet established sedation criteria~* Refuses administration of study medication prior to sedation~* History of allergy, intolerance, or reaction to dexmedetomidine or propofol or hypersensitivity~* Current, repaired or risk of Moya-Moya disease~* Recent stroke (cerebrovascular accident) within past 6 months~* Uncontrolled hypertension~* Concomitant use of opioids, beta antagonist, alpha 2 agonist or calcium channel blocker~* Egg, soy or lecithin allergy~* BMI greater than 30 or weight above 110th percentile~* Refuses insertion of intravenous catheter while awake~* Currently receiving pharmacologic agents for hypertension or cardiac disease~* Currently receiving or has received digoxin within the past 3 months~* Active, uncontrolled gastroesophageal reflux - an aspiration risk~* Current (or within past 3 months) history of apnea requiring an apnea monitor~* Unstable cardiac status (life threatening arrhythmias, abnormal cardiac anatomy, significant cardiac dysfunction)~* Craniofacial anomaly, which could make it difficult to effectively establish a mask airway for positive pressure ventilation if needed~* Active, current respiratory issues that are different from the baseline status (pneumonia, exacerbation of asthma, bronchiolitis, respiratory syncytial virus)

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Propofol (Group P) (Type: ACTIVE_COMPARATOR): Propofol only
- Propofol with Dexmedetomidine (Group DP) (Type: ACTIVE_COMPARATOR): Propofol with Dexmedetomidine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The EndoGastric Solutions TEMPO Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-80 years;~2. GERD for \> 1 year;~3. History of daily PPIs for \> 6 months;~4. At least daily bothersome medically refractory GERD symptom(s) other than heartburn on PPIs;~5. Hill grade I and II at gastroesophageal junction;~6. Proven gastroesophageal reflux by either endoscopy, ambulatory pH or barium swallow testing;~7. Willingness to undergo pH testing;~8. Willingness to cooperate with the postoperative diet;~9. Availability for follow-up visits at 6, 12, 24, and 36 months;~10. Willingly and cognitively signed inform consent~Exclusion Criteria:~1. BMI \> 35 Hiatal hernia \> 2c m in axial height and \> 2 cm in greatest transverse dimension;~2. Esophagitis grade C and D;~3. Barrett's esophagus \> 2 cm;~4. Esophageal ulcer;~5. Fixed esophageal stricture or narrowing;~6. Portal hypertension and/or varices;~7. Active gastro-duodenal ulcer disease; Gastric outlet obstruction or stenosis;~8. Gastroparesis;~9. Coagulation disorders;~10. History of any of the following: resective gastric or esophageal surgery, antireflux surgery with anatomy unsuitable for TIF procedure per physician judgment, cervical spine fusion, Zenker's diverticulum, esophageal epiphrenic diverticulum, achalasia, scleroderma or dermatomyositis, eosinophilic esophagitis, or cirrhosis;~11. Pregnancy or plans of pregnancy in the next 12 months;~12. Enrollment in another device or drug study that may confound the results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Transoral incisionless esophago-gastric fundoplication using the EsophyX system with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA) and following TIF2.0 protocol.
- Control (Type: ACTIVE_COMPARATOR): Patients who are dependent upon daily PPIs will continue on single dose twice daily or increase to single dose twice daily for the first six months of the clinical trial. Patients will be offered TIF crossover procedure upon completion of month-6 follow-up visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-80~* Symptom onset less than 24 hrs prior to diagnostic CT scan~* Spontaneous ICH less than or equal to 30 cc or primary IVH~* IVH obstructing 3rd and/or 4th ventricles~* ICH clot stability at 6 hours or more post IVC placement~* IVH clot stability at 6 hours or more post IVC placement~* Catheter tract bleeding stability 6 hours or more post IVC placement~* EVD placed per standard medical care~* SBP less than 200 mmHg sustained for 6 hours prior to drug administration~* Able to randomize within 72 hours of diagnostic CT scan~* Historical Rankin of 0 or 1~Exclusion Criteria:~* Suspected or untreated ruptured cerebral aneurysm, AVM, or tumor~* Presence of a choroid plexus vascular malformation or Moyamoya~* Clotting disorders~* Platelet count less than 100,000, INR greater than 1.4~* Pregnancy~* Infratentorial hemorrhage~* SAH at clinical presentation~* ICH/IVH enlargement that cannot be stabilized in the treatment time window~* Ongoing internal bleeding~* Superficial or surface bleeding~* Prior enrollment in the study~* Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated~* Planned or simultaneous participation (between screening and Day-30) in another interventional medical investigation or clinical trial.~* No subject or legal representative to give written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Alteplase (Type: EXPERIMENTAL): administration of alteplase via the intraventricular catheter
- Saline Placebo (Type: PLACEBO_COMPARATOR): 1 ml of normal saline administered via the intraventricular catheter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound Assisted Wound Debridement (UAW) Versus Standard Wound Treatment in Complicated Diabetic Foot Ulcers (DFU)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Male and female patients ≥18 years old~  * Type 1 or type 2 diabetes with levels of HbA1c≤85.8 mmol/mol (10%) within 30 days of the beginning of the study~ * Wound stages IB, IIB, ID, and IID according to the University of Texas Diabetic Wound Classification \[11\]~ * Wound duration of 1-24 months~ * Wound size between 1-30 cm2 after debridement~ * Clinical picture of wounds showing mild or moderate infection, according to the criteria of the Infectious Disease Society of America Guidelines \[12\] and the European Wound Management Association (EWMA) \[13\]~ * Ankle-brachial index (ABI) ≤0.9 and ankle systolic blood pressure (ASBP) ≥70mmHg, or toe systolic blood pressure (TSBP) ≥50mmHg, ABI\>0.9, TSBP ≥50mmHg and toe-brachial index (TBI) ≤0.7~Exclusion Criteria:~* • Chronic renal disease or dialysis~  * Non-treated osteomyelitis~ * Necrotizing soft tissue infections~ * Critical limb ischaemia patients with ABI≤0.5 and ASBP\<70mmHg or \<50mmHg~ * Life expectancy \<6 months due to malignant DFU~ * Pregnancy and lactation~ * Patients diagnosed with hepatitis or human immunodeficiency virus (HIV)~ * Patients showing local or systemic conditions that may impair tissue repair

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ultrasound Group (UAW group) (Type: EXPERIMENTAL): UAW debridement was performed using an UAW SONOCA 185 device (Söring GmbH, Germany). The UAW device generates an ultrasound low frequency of 25kHz and is equipped with three UAW instruments with different sonotrode shapes. The choice of sonotrode depends on wound depth, which ranges from superficial to deep. The UAW instrument piezoelectrically transforms the electrical energy delivered from the UAW device into mechanical oscillations in the sonotrode tip. For most wounds in the UAW group, a two-minute treatment with 40% intensity was performed by holding the sonotrode in contact mode, holding it perpendicular to the wound bed and moving it across in an up-and-down pattern.
- Surgical group (Type: ACTIVE_COMPARATOR): All debridement procedures were performed by the same surgeon (J.L.M.), who is specialist in diabetic foot surgery with more than 20 years of experience.~Surgical debridement involved removal of all necrotic and devitalized tissue that was incompatible with healing, as well as surrounding callus.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Topical Bupivacaine and Triamcinolone Acetonide Injection in the Relief of Pain After Endoscopic Submucosal Dissection for Gastric Neoplasia: A Randomized Double-blind, Placebo-controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age, between 20 and 80~* Patients who were scheduled to undergo ESD for gastric epithelial neoplasm at Severance Hospital between July 2012 and April 2013~Exclusion Criteria:~* Not providing written informed consent~* A history of any cardiac arrhythmias~* Current or regular use of analgesic medication for other indications~* Known other disease such as peptic ulcer disease or reflux esophagitis which could induce upper gastrointestinal pain~* Multiple lesions requiring ESD in a single patient~* Evidence of infectious disease or antibiotics therapy within 7 days prior to enrollment~* Participation in another clinical trial within 30 days prior enrollment~* Current pregnancy or breast feeding.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): None
- Bupivacaine only group (Type: EXPERIMENTAL): None
- Bupivacaine with triamcinolone group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Have received at least 2 administrations of intravenous (iv) hydration separated by at least 1 week or daily emesis for at least the last 14 days and 1 administration of iv hydration.~2. Have at least one of the following: 2-4+ ketonuria, serum potassium \< 3.4mmol, or \>5% weight loss from weight upon entry to prenatal care.~3. Have failed therapy with at least one antiemetic.~4. Have fetal ultrasound within 6 weeks prior to enrollment confirming a normal-appearing, intrauterine, singleton pregnancy of gestational age \< 16 weeks at time of enrollment.~5. Felt by the patient's obstetrician or emergency room attending physician not to have other medical problems such as bowel obstruction, pancreatitis, biliary colic, or peptic ulcer disease that could be contributing to the patient's symptoms.~6. Be \>18 years old and not decided to terminate the pregnancy.~7. Have not received or planning to receive a peripherally inserted central catheter (PIC line).~8. Have a Motherisk-PUQE score of ≥12 for the 24-hour Baseline period.~9. Felt not to have any other significant medical, psychiatric or substance abuse problem that would preclude participation in the study.~10. Denies drinking any alcohol after learning about current pregnancy.~11. Agrees to discontinue any current anti-emetic treatments (including antihistamines, ginger, \> 10mg/day vitamin B6, serotonin or dopamine antagonists, anticholinergics, acupuncture, hypnosis, or wrist bands) for the next 4 weeks.~12. Pregnancy not conceived through in-vitro fertilization.~13. Able to understand and comply with the study procedures and give informed consent.~Exclusion Criteria:~None not mentioned under Inclusion Criteria.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- gabapentin (Type: EXPERIMENTAL): 1800-2400mg/day divided tid or qid, orally.
- metoclopramide (Type: EXPERIMENTAL): 45-60mg/day divided tid or qid, orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or non-pregnant females, ≥12 years of age, of any race or sex. Females of child-bearing potential must have a negative urine pregnancy test.~* Presence of interdigital only or both interdigital and moccasin types of tinea pedis on one or both feet characterized by clinical evidence of a tinea infection (at least moderate erythema, moderate scaling and mild pruritus) based on signs and symptoms in the affected area(s)).~Exclusion Criteria:~* Subjects with life-threatening condition (ex. autoimmune deficiency syndrome, cancer,unstable angina or myocardial infarction) within the last 6 months.~* Subjects with abnormal findings - physical or laboratory - that are considered by the investigator to be clinically important and indicative of conditions that might complicate interpretation of study results.~* Subjects with a known hypersensitivity to study drugs or their components.~* Subjects who have a recent history or who are currently known to abuse alcohol or drugs.~* Uncontrolled diabetes mellitus.~* Hemodialysis or chronic ambulatory peritoneal dialysis therapy.~* Current diagnosis of immunocompromising conditions.~* Foot psoriasis, corns and/or callus involving any web spaces, atopic or contact dermatitis.~* Severe dermatophytoses, onychomycosis (on the evaluated foot), mucocutaneous candidiasis or bacterial skin infection.~* Extremely severe tinea pedis (incapacitating).~* Female subject who is pregnant or lactating, who is not using or does not agree to use an acceptable form of contraception during the study, or who intends to become pregnant during the study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NAFT-600 ( naftin 2 % gel) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* body weight ≥40 kg and ≤125 kg~* previously documented CHC genotype 1 infection;~* must have a liver biopsy with histology consistent with CHC and no other etiology~* if cirrhosis present, must have an ultrasound within 6 months of the screening visit (or between screening and Day 1) with no findings suspicious for hepatocellular carcinoma (HCC)~* agree to use acceptable methods of contraception with partner~* previously untreated with pegylated-interferon (either alfa-2a or alfa-2b) plus RBV or failing prior treatment with pegylated-interferon (either alfa-2a or alfa-2b) plus RBV~Exclusion criteria:~* co-infected with the human immunodeficiency virus (HIV) or hepatitis B virus (Hepatitis B surface antigen \[HBsAg\] positive).~* required discontinuation of previous interferon or ribavirin regimen for an adverse event (possibly or probably related)~* treatment with ribavirin within 90 days and any interferon-alpha, based on the amendment, should be within 1 month prior to screening~* treatment with any investigational drug within 30 days of the screening visit in this trial~* evidence of decompensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding varices, or hepatic encephalopathy~* diabetic and/or hypertensive with clinically significant ocular examination findings~* clinical diagnosis of substance abuse of specified drugs within specified timeframes~* any known pre-existing medical condition that could interfere with the participant's participation in and completion of the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RGT BOC + PR (Type: EXPERIMENTAL): Participants received PR for 4 weeks before addition of BOC. Participants then received response guided therapy (RGT) with BOC + PR for up to 32 weeks followed by PBO + PR for up to 20 weeks.
- PBO + PR (Control) (Type: PLACEBO_COMPARATOR): Participants received PR for 4 weeks before addition of BOC-matched PBO. Participants then received BOC + PR for up to 44 weeks.
- Crossover Arm (Type: EXPERIMENTAL): Participants randomized to the PBO + PR Control arm who failed the futility rule at treatment week (TW) 12 or 24 were rolled over to the Crossover arm and received BOC + PR.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exacerbation Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female adults aged ≥40 years, who have signed an Informed Consent form prior to initiation of any study-related procedure~* Patients diagnosed with COPD at age 40 and over and with a current diagnosis of severe COPD and including:~  1. Smoking history of at least 10 pack years, both current and ex-smokers are eligible~ 2. A documented history of at least 1 moderate or severe exacerbation in the previous 12 months~Exclusion Criteria:~* Patients who have received systemic corticosteroids and/or antibiotics for a COPD exacerbation in the 6 weeks prior to screening or during the run-in period~* Patients who have had a respiratory tract infection within 6 weeks prior to screening~* Patients with concomitant pulmonary disease~* Patients with a history of asthma~* Patients with diabetes Type I or uncontrolled diabetes Type II~* Any patient with lung cancer or a history of lung cancer~* Patients with a history of certain cardiovascular comorbid conditions~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indacaterol (Type: EXPERIMENTAL): Indacaterol 150 µg o.d. delivered via single-dose dry powder inhaler (SDDPI)
- Tiotropium (Type: ACTIVE_COMPARATOR): Tiotropium 18 µg o.d. delivered via the handihaler®

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Trial of Neo-adjuvant Temozolomide Prior to Combined Temozolomide and Concurrent Accelerated Hypofractionated External Beam Radiotherapy Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18 years or older~* Histological confirmation of supratentorial GBM~* KPS \> 60~* Neurological function 0 or 1~* Adequate bone marrow as defined below:~* absolute neutrophil count (ANC) \> 1500 cells/mm3~* platelets \> 100,000 cells/mm3~* hemoglobin \> 10g/dl~* Adequate renal function as defined below:~* BUN \< 25mg/dl within 14 days prior to study registration~* creatinine of 63 to 103 umol/L within 14 days prior to study registration~* Adequate hepatic function as defined below:~* Bilirubin of 3 to 21 umol/L within 14 days prior to study registration~* ALT \& AST \< 3xnormal range within 14 days prior to study registration~* Neoadjuvant TMZ to start within 3 weeks of surgery/biopsy if no resection was deemed feasible~* A diagnostic contrast-enhanced MRI or CT scan of the brain must be performed preoperatively and postoperatively.~* History, physical and neurological examination within 14 days prior to study registration.~* For females of child-bearing potential, negative pregnancy test within 72 hours prior to starting TMZ.~* Able to sign an informed study-specific consent~Exclusion Criteria:~* Margin of contrast-enhanced residual mass closer than 15mm from the optic chiasm or optic nerves.~* Prior invasive malignancy, unless disease-free for \>3years~* Recurrent or multifocal GBM~* Severe co-morbidities such as~* unstable angina~* transmural myocardial infarction within 6 months~* COPD at the time of registration~* Hepatic insufficiency~* Bacterial or fungal infection requiring IV antibiotics at the time of registration~* Acquired Immune Deficiency Syndrome (AIDS)~* Major medical illnesses or psychiatric impairments~* Pregnant women or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Temozolomide, Accelerated Hypofractionated RT (Type: EXPERIMENTAL): Patient will receive two weeks of neo-adjuvant Temozolomide followed by Accelerated Hypofractionated RT for a total of 20 fractions for a total of 60Gy followed by Temozolomide for 12 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete